Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448333 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CA12CA9MAPTKDM4E | |
| Ethylene SCHEMBL9096059 | 0.96 | ALDH1A1 (0.70) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL20876339 | 0.85 | ALDH1A1 (0.71) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL4681571 | 0.85 | ALDH1A1 (0.71) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL10671092 | 0.83 | ALDH1A1 (0.59) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL14282655 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL8940040 | 0.83 | CA12 (0.73) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL1274905 | 0.82 | ALDH1A1 (1.00) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL29744481 | 0.81 | CA12 (1.00) | ALDH1A1CA12CA9MAPTKDM4E | |
| SCHEMBL11148327 | 0.81 | CA12 (0.70) | ALDH1A1CA12CA9MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| US-12275741-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2024-08-01 | — | — | US | disclosed |
| EP-0254245-B1 | Hetrazepins and processes for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1994-09-28 | — | — | EP | disclosed |
| US-5211738-A | ADENINE DERIVATIVES AND THEIR USE AS A PLANT GROWTH REGULATOR | MITSUBISHI GAS CHEMICAL CO., INC. (JP) | 1993-05-18 | — | — | US | disclosed |
| US-5190589-A | Compounds and process preparing a substituted or an unsubstituted 4(5)-(ω-aminoalkyl)imidazole | CEDONA PHARMACEUTICALS B.V. (NL) | 1993-03-02 | — | — | US | disclosed |
| EP-0508777-A2 | Novel adenine derivatives and their use as plant growth regulators | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1992-10-14 | — | — | EP | disclosed |
| EP-0415948-A1 | PROCESS FOR PREPARING A SUBSTITUTED OR AN UNSUBSTITUTED 4(5)-($g(v)-AMINOALKYL)IMIDAZOLE | CEDONA PHARMACEUTICALS B.V. (NL) | 1991-03-13 | — | — | EP | disclosed |
| WO-1989010360-A1 | PROCESS FOR PREPARING A SUBSTITUTED OR AN UNSUBSTITUTED 4(5)-(omega-AMINOALKYL)IMIDAZOLE | CEDONA PHARMACEUTICALS B.V. (NL) | 1989-11-02 | — | — | WO | disclosed |
| US-RE32868-E | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1989-02-14 | — | — | US | disclosed |
| EP-0254245-A1 | Hetrazepins and processes for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1988-01-27 | — | — | EP | disclosed |
| US-4395417-A | Antihyperlipidemic compositions | RESEARCH CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-3992408-A | CHEMICAL INTERMEDIATES | THE UPJOHN COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254128-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | ALDH1A1 3106/4885CA12 4885/4885CA9 4847/4885 |
| US-12275741-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885CA12 4807/4885CA9 4613/4885 |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | ALDH1A1 3175/4885CA12 1813/4885CA9 1004/4885 |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885CA12 4807/4885CA9 4613/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | ALDH1A1 3517/4885CA12 4807/4885CA9 4613/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ALDH1A1 569/4885CA12 4350/4885CA9 2534/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | ALDH1A1 3106/4885CA12 4885/4885CA9 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.